Tag: Aria

In clinical trials for donanemab (brand name Kisunla), approximately 37% of participants experienced amyloid-related imaging abnormalities (ARIA), a key safety consideration for this Alzheimer's treatment. Understanding **what are the side effects of the drug donanemab?** is crucial for patients, caregivers, and clinicians considering this therapy.

In clinical trials, Leqembi was shown to slow the rate of cognitive decline in early Alzheimer's disease by 27% over 18 months compared to a placebo, but some patients and caregivers still ask, "Can Leqembi make Alzheimer's worse?". The answer is complex, as it involves understanding the difference between the disease's natural progression and serious, drug-related adverse events.

In clinical trials for the Alzheimer's medication LEQEMBI (lecanemab), up to 12.6% of patients experienced brain swelling (ARIA-E) and 17.3% experienced brain bleeding (ARIA-H), which was higher than in the placebo group. While often asymptomatic, these side effects can, in rare cases, manifest with serious, stroke-like symptoms or lead to fatal brain hemorrhages, raising concerns about if **LEQEMBI can cause a stroke**. The U.S. Food and Drug Administration (FDA) has issued a black box warning to highlight this significant safety risk.

In the pivotal Clarity AD clinical trial, 12.6% of participants treated with Leqembi developed brain swelling (ARIA-E), a condition where confusion can be a key symptom [1.4.6]. The question of 'Can Leqembi cause confusion?' is directly linked to this and other potential side effects.

In clinical trials, common Leqembi side effects, such as infusion reactions and headaches, typically lasted for a few days to several weeks before resolving. However, the duration of side effects can vary significantly depending on the type and severity, with some serious adverse events like ARIA taking months to fully resolve.

Three deaths were assessed as related to donanemab treatment due to amyloid-related imaging abnormalities (ARIA) during the TRAILBLAZER-ALZ 2 trial, prompting a closer examination of the drug's safety profile. The question of 'How many people died in the donanemab trial?' has become central to discussions surrounding this new Alzheimer's medication, balancing its efficacy with significant safety concerns.

The term "Aria drug" is highly ambiguous, as it can refer to the brand-name biologic infusion **Simponi Aria**, or be confused with **ARIA**, an imaging abnormality seen with certain Alzheimer's disease medications. In fact, Simponi Aria is a prescription medication, while ARIA is a documented side effect, representing two completely different pharmaceutical contexts. This guide will explain the difference and provide clarity on both important medical topics.

In July 2024, the FDA granted traditional approval for **donanemab** (marketed as Kisunla™), a monoclonal antibody that targets and helps clear amyloid plaques in patients with early symptomatic Alzheimer's disease. This represents a significant advancement in treating the underlying pathology of the disease rather than just managing symptoms.

The U.S. Food and Drug Administration (FDA) approved donanemab (brand name Kisunla) in July 2024 for treating early symptomatic Alzheimer's disease. This monoclonal antibody, developed by Eli Lilly, is specifically designed to target and help clear beta-amyloid plaques from the brain. Understanding the meaning of Donanemab involves grasping its innovative mechanism and potential to slow the disease's progression.